Thank you for your participation!
Joseph B. Martin Conference Center
at Harvard Medical School
77 Avenue Louis Pasteur, Boston, MA 02115
About the Conference
The First Stop for Growing Your
The 15th Annual Trans-Pacific Health Sciences Dialogue is a meeting for biopharmaceutical industry executives and business development executives who want to accelerate, explore and develop collaborations and partnerships with their counterparts in the most important Trans-Pacific health care markets including Japan, China, South Korea and North America.
This is a must-attend meeting for executives who have, or want to develop, a Trans-Pacific strategy. The event has developed a well-earned reputation as the best place for biopharma companies seeking to forge Trans-Pacific ventures to start exploring their options. Attendees come away with a broad overview and insights they simply will not get in other meetings.
Take a look at some photos from the 2016 Trans-Pacific Health Sciences Dialogue!
Industry News from FiercePharmaAsia
- Sun's profit crushed as it pays $150M to settle Provigil pay-for-delay caseSun Pharma has been stung by a decade-old pay-for-delay lawsuit, one of a host of issues that contributed to a 74% slide in its profit last quarter for India's largest drugmaker, even after the litigation cost was backed out.
- FiercePharmaAsia—Sun’s quarterly loss, BeiGene’s $175M public offering, Biocon plant’s extensive problemsSun Pharma's U.S. sales for the previous quarter dropped 42%, BeiGene is offering another follow-up public offering of $175 million and the FDA issued an 8-page Form 483 to Biocon's sterile manufacturing plant expected to produce a Herceptin biosimilar.
Who Should Attend
The Trans-Pacific Health Sciences Dialogue is an event for biopharmaceutical executives, KOLs, select industry advisors and members of the financial community with a strategic interest in Trans-Pacific collaboration or investment.